Your browser doesn't support javascript.
loading
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Cassier, Philippe A; Italiano, Antoine; Gomez-Roca, Carlos; Le Tourneau, Christophe; Toulmonde, Maud; D'Angelo, Sandra P; Weber, Kristy; Loirat, Delphine; Jacob, Wolfgang; Jegg, Anna-Maria; Michielin, Francesca; Christen, Randolph; Watson, Carl; Cannarile, Michael; Klaman, Irina; Abiraj, Keelara; Ries, Carola H; Weisser, Martin; Rüttinger, Dominik; Blay, Jean-Yves; Delord, Jean-Pierre.
  • Cassier PA; Centre Léon Bérard, Département D'Oncologie Médicale, Lyon, France.
  • Italiano A; Institut Bergonie, Oncologie, Bordeaux, France.
  • Gomez-Roca C; Institut Claudius Regaud, Département D'Oncologie Médicale, Toulouse, France.
  • Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France; INSERM U900 Research Unit, Saint-Cloud, France; Paris-Saclay University, Paris, France.
  • Toulmonde M; Institut Bergonie, Oncologie, Bordeaux, France.
  • D'Angelo SP; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA.
  • Weber K; University of Pennsylvania, Philadelphia, USA.
  • Loirat D; Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France.
  • Jacob W; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany. Electronic address: wolfgang.jacob@roche.com.
  • Jegg AM; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
  • Michielin F; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Christen R; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Watson C; A4P Ltd, Sandwich, UK.
  • Cannarile M; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
  • Klaman I; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
  • Abiraj K; Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Ries CH; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
  • Weisser M; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
  • Rüttinger D; Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
  • Blay JY; Centre Léon Bérard, Département D'Oncologie Médicale, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Unicancer, Paris, France.
  • Delord JP; Institut Claudius Regaud, Département D'Oncologie Médicale, Toulouse, France.
Eur J Cancer ; 141: 162-170, 2020 12.
Article en En | MEDLINE | ID: mdl-33161240
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Sinovitis Pigmentada Vellonodular / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Sinovitis Pigmentada Vellonodular / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article